Myiasis was first described by Hope in 1840. Since then, many cases of myiasis affecting different human organs have been reported. Oral myiasis is very rare in healthy persons but occurs mainly in the tropics and associated with inadequate public and personal hygiene. In this case report, we present clinical findings gingival myiasis. The patient was 26-year-old farmer and his chief complaint was discomfort and swelling in his maxillary gingiva. The patient's medical and family histories were non-contributory and oral hygiene was not acceptable. The diagnosis was based on the characteristic clinical features and the visual presence of wriggling larvae about 1 cm in size. The larvae were identified as Calliphoridae. Treatment consisted of removal of the maggots from the gingival sulcus, followed by scaling and oral hygiene instruction. One week later, a periodontal flap operation was done. The patient was followed-up for 6 months and healing was uneventful.
Objective. The purposes of this study were to determine whether secnidazole administered at a single dose of 10 mg/kg, orally, lessens or eliminates Giardia cyst shedding, and to validate the benefit of secnidazole treatment on clinical signs and faecal consistency in lambs naturally infected with Giardia duodenalis. Materials and methods. To this extent weaned 12 weeks of age lambs were selected and randomly assigned into two groups based on placebo (group C, n=7 untreated control group) or treatment (group S, n=10 lambs treated with a single dose of secnidazole at 10 mg/kg). Results. On days 0 and 10, before and after treatment, respectively, reduction in cyst excretion was determined. The faecal consistency and general health were recorded at each sampling day. Conclusions. During the study there was a high (99.98%) reduction in cyst excretion in the secnidazol treatment group compared to the positive control group on day 10, resulting in a significant (p<0.001) reduction, making secnidazole highly effective treatment option.Key words: Clinics, evaluation, lamb, secnidazol (Source: CAB). RESUMENObjetivo. El objetivo de este estudio fue determinar si la administración oral de una dosis única de secnidazol de 10mh/kg reduce o elimina la presencia de quistes de Giardia y validar el beneficio del tratamiento con secnidazol en los signos clínicos y la consistencia fecal de corderos infectados naturalmente con Giardia duodenalis. Materiales y métodos. Se seleccionaron corderos destetados de 12 semanas de edad que fueron asignados al azar a dos grupos con base a placebo (grupo C, n=7, grupo de control sin tratar) o tratamiento (grupo S, n=10 corderos con tratamiento de dosis única de secnidazol de 10 mg/kg). Resultados. En los días 0 y 10, antes y después del tratamiento, respectivamente, se determinó una merma en la excreción de quistes. La consistencia de la materia fecal y el estado general de salud fue registrado en cada muestreo diario. Conclusiones. Durante el estudio hubo una alta reducción en la excreción de quistes (99.98%) en el grupo tratado con secnidazol comparado con el grupo control positivo en el día 10, resultando en una disminución significativa (p<0.001), haciendo del tratamiento con secnizadol una opción altamente efectiva.
Otomyiasis was diagnosed in the right ear of a 3-month-old goose. Twenty-three of 25 larvae were in the meatus acusticus externus, and 2 larvae were under the skin. The larvae were in the third larval stage of Sarcophaga spp. by microscopic examination. A case of otomyiasis was reported in goose for the first time in the world on the basis of morphological characteristics (macroscopic and microscopic evaluation) in this communication.
The aim of the present study was to identify the haplotypes of the Varroa destructor mite which infects honeybees (Apis mellifera) in the province of Aydın in Turkey, using two different modified techniques for the mitochondrial Cox1 gene of the mite. In order to confirm the haplotype, two different primer pairs were selected. 376 bp DNA in size was amplified using the first primer pair. SacI restriction enzyme was applied to the amplified products; however, this restriction enzyme did not cut the DNA. 570 bp DNA in size was amplified using the second primer pair. XhoI and SacI restriction enzymes were used for the amplified products. Although, the SacI restriction enzyme did not cut the DNA, the XhoI restriction enzyme cut the amplified DNA into two fragments (bands), with the sizes of 270 and 300 bp two bands 270 and 300 bp. While comparing the results, these bands were found specific for Korean haplotype of V. destructor. In conclusion, all of the 200 samples of V. destructor examined in this study were identified to be the Korean haplotype. Öz: Bu çalışmada; Aydın bölgesinde bal arılarında (Apis mellifera) görülen Varroa destructor'un mitokondriyal Cox1 geninin haplotiplerinin belirlenmesi amacıyla farklı iki teknik modifiye edilerek uygulanmıştır. Haplotip belirlenmesi amacıyla iki farklı primer çifti seçilmiştir. Birinci primer çiftiyle 376 bp büyüklüğünde DNA amplifiye edilmiştir. Amplifiye ürüne SacI restriksiyon enzimi uygulanmış ancak bu restriksiyon enziminin DNA'yı kesmediği görülmüştür. İkinci primer çiftiyle 570 bp büyüklüğünde amplifiye DNA elde edilmiştir. Elde edilen amplifiye DNA'ya XhoI restriksiyon enzimi ve SacI restriksiyon enzimleri uygulanmıştır. Ancak SacI restriksiyon enziminin DNA'yı kesmediği, XhoI restriksiyon enziminin ise elde edilen genomik DNA amplifikasyonunda 270 ve 300 bp büyüklüğünde iki band oluşturduğu saptanmıştır. Sonuçlar karşılaştırıldığında; elde edilen bandların V. destructor Kore haplotipi için spesifik olduğu tespit edilmiştir. Sonuç olarak; V. destructor'un haplotipinin belirlenmesine yönelik yapılan bu araştırmada, incelenen 200 örneğin tamamının V. destructor Kore haplotipi olduğu saptanmıştır.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.